HUYABIO International, a global developer of novel biopharmaceutical product opportunities originating in China, announced on Tuesday that it has treated its first patient in a pivotal trial aimed at measuring the safety and efficacy of HBI-8000 combined with Bristol Myers Squibb's anti-PD-1, antibody Opdivo (nivolumab), to treat patients with unresectable or metastatic melanoma.
The multicentre, randomised, double blinded, placebo-controlled Phase 3 trial is named 'Study Comparing the Investigational Drug HBI-8000 Combined with Opdivo vs. Opdivo in Patients with Advanced Melanoma'. It will have a primary outcome of objective response rate and progression-free survival, while secondary outcomes include safety and overall survival.
The trial is to enrol 480 patients from the United States, Europe, Australia, New Zealand and Japan. HBI-8000, an epigenetic immunomodulator, is approved in China to treat lymphoma and metastatic breast cancer.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients